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The mechanisms by which prostate cancer shifts from an indolent castration-sensitive phenotype to lethal castration-
resistant prostate cancer (CRPC) are poorly understood. Identification of clinically relevant genetic alterations leading to
CRPC may reveal potential vulnerabilities for cancer therapy. Here we find that CUB domain-containing protein 1
(CDCP1), a transmembrane protein that acts as a substrate for SRC family kinases (SFKs), is overexpressed in a subset
of CRPC. Notably, CDCP1 cooperates with the loss of the tumor suppressor gene PTEN to promote the emergence of
metastatic prostate cancer. Mechanistically, we find that androgens suppress CDCP1 expression and that androgen
deprivation in combination with loss of PTEN promotes the upregulation of CDCP1 and the subsequent activation of the
SRC/MAPK pathway. Moreover, we demonstrate that anti-CDCP1 immunoliposomes (anti–CDCP1 ILs) loaded with
chemotherapy suppress prostate cancer growth when administered in combination with enzalutamide. Thus, our study
identifies CDCP1 as a powerful driver of prostate cancer progression and uncovers different potential therapeutic
strategies for the treatment of metastatic prostate tumors.
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Introduction
Castration-resistant prostate cancer (CRPC) is the second leading 
cause of death among men in developed countries (1). Although 
second-generation androgen-deprivation therapies (ADTs) have 
been successfully used to treat CRPC, patients develop resistance 
and eventually succumb to the disease (2). Mechanisms of resis-
tance in CRPCs include, among others, activation of androgen 
receptor (AR) (i.e., AR amplification, mutations, or splicing vari-
ants) and upregulation of signaling pathways promoting AR inde-
pendent growth, such as the PI3K/AKT and MAPK pathways that 
are mutually deregulated in CRPCs (3–6). Although in metastatic 
prostate cancers the PI3K signaling pathway is activated by the 
loss or mutations of the tumor suppressor PTEN (7), the mecha-
nism by which the MAPK pathway is upregulated remains partially 
unknown. Interestingly, activation of the MAPK pathway by K-RAS 
in a PTEN-deficient prostate cancer mouse model leads to the 
development of metastatic prostate cancer (8). However, mutations 
of either KRAS or BRAF account for only a minority of human pros-
tate cancer cases (5, 9, 10). Thus, the identification of new regula-
tors of this pathway, in the context of PTEN-null prostate cancers, 
would open the way to new effective therapies for the treatment of 
this disease. The Pten-null prostate conditional mouse model pro-
vides an excellent tool to study prostate tumorigenesis. Pten defi-
ciency in the mouse prostate epithelium leads to benign prostate 
tumors characterized by a senescence response that opposes tumor 
progression (11, 12). Therefore, this model can be used to identify 
pathways or genes that serve as the “second hit” for the evasion of 
senescence, acquisition of metastatic potential, and the preclinical 
validation of new therapies in this setting (12–14).
CUB domain-containing protein 1 (CDCP1), also known as 
SIMA135 (15), gp140 (16), CD318 (17), or Trask (18), is a trans-
membrane protein that is frequently overexpressed in a variety of 
human cancers (19–21). Several papers demonstrate that CDCP1 
is a potent oncogene that drives cancer development, invasion, 
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PTEN and high levels of CDCP1 increased in CRPCs and meta-
static tumors when compared with primary tumors, thereby val-
idating the clinical relevance of this anti-correlation (Figure 1, C 
and D, and Tables 3 and 4). Additionally, bioinformatics analysis 
evaluating different data sets confirmed the existence of an anti- 
correlation between PTEN and CDCP1 mRNA levels (Supplemen-
tal Figure 1, C and D). Elevated levels of CDCP1 expression were 
also significantly associated with PTEN genetic deletions and low 
CDCP1 promoter methylation in different independent data sets 
of PCa (Figure 1E and Supplemental Figure 1, E and F). Although 
patients affected by prostate tumors harboring a high level of 
CDCP1 had a similar disease-free survival (DFS) as patients with 
low CDCP1, patients with tumors expressing low levels of PTEN 
and an increased level of CDCP1 had a significantly shorter DFS 
than patients in the other categories (Figure 1F and Supplemental 
Figure 1G). Taken together, these data validate the clinical rele-
vance of CDCP1 and suggest that CDCP1 could cooperate with 
the loss of PTEN to promote highly aggressive prostate cancer.
Conditional overexpression of CDCP1 in the mouse prostate and 
Drosophila melanogaster initiates tumorigenesis. To model CDCP1 
overexpression in cancer, we generated a CDCP1 transgenic 
mouse model. At first, we constructed a pCAGGS vector with a 
transcriptional STOP sequence flanked by loxP sites upstream of 
CDCP1-cDNA. The resulting pCAGGS-loxP-STOP-loxP-CDCP1 
vector along with PGK-FlpO plasmid were coelectroporated into 
the ColA locus of modified KH2 embryonic stem cells (ref. 33 and 
Supplemental Figure 2A). PCR and Southern blot analysis con-
firmed gene integration and recombination events (Supplemental 
Figure 2B). Next, we crossed CDCP1 with PB-Cre4 mice for pros-
tate-specific expression of CDCP1 (34). IHC, reverse transcription 
PCR (RT-PCR), and Western blot analyses were performed on 
prostate tissues of 10-week-old CDCP1 Pb-Cre mice (CDCP1pcLSL/+, 
hereafter referred to as CDCP1+) and confirmed the prostate- 
specific expression of CDCP1 (Supplemental Figure 2, C–E). Of 
note, the expression of CDCP1 in a panel of human prostate tumor 
cell lines, patient-derived prostate cancer xenografts (PDXs), 
and tumors collected from CDCP1+ mice did not show significant 
differences in CDCP1 levels (Supplemental Figure 2F), thereby 
demonstrating that overexpression of CDCP1 in the mouse model 
is similar to the CDCP1 levels in human tumors. Next, we exam-
ined tumor incidence in CDCP1 mice over 24 months. CDCP1 mice 
developed prostate hyperplasia between 4 and 6 months of age 
at 50% penetrance. CDCP1 mice between 7 and 9 months of age 
developed a high penetrance of PIN (prostatic intraepithelial neo-
plasia) lesions characterized by multilayered epithelial cells with 
features of nuclear atypia. These mice further developed high-
and metastases. In cells cultured in adherent conditions, CDCP1 
overexpression promotes the activation of Src-family members 
(SFKs), phosphorylation of protein kinase C delta (PKC-δ), and 
the upregulation of the MAPK/ERK pathway (22). In contrast with 
these results, recent studies reported that loss of CDCP1, in cells 
kept in nonadherent conditions, supports tumor cells prolifera-
tion by differentially regulating SRC activity (23–25). Interesting-
ly, CDCP1 targeting, either with monoclonal antibodies or small 
molecule inhibitors, has demonstrated effectiveness at inhibiting 
tumor growth and metastasis in vivo (26–28). Since treatments 
with either SRC or MAPK inhibitors have been associated with 
poor tolerability in the clinic (29), CDCP1 targeting could repre-
sent an excellent and alternative therapeutic option. In the pres-
ent manuscript, we show that CDCP1 is overexpressed in a subset 
of advanced human CRPCs, and cooperates with loss of PTEN to 
promote the emergence of this disease. Moreover, we have found 
that AR represses CDCP1 transcription, whereas ADTs promote 
the upregulation of CDCP1 in tumor cells harboring PTEN dele-
tions, thereby increasing the activation of the SRC/MAPK path-
way. Notably, treatment of anti–CDCP1 ILs loaded with chemo-
therapy in combination with enzalutamide substantially inhibits 
prostate tumor progression. Our results introduce what we believe 
is a previously unknown and exciting therapeutic strategy to treat 
PTEN-deficient prostate cancer patients.
Results
CRPC and metastatic prostate tumors exhibit elevated expression of 
CDCP1, and overexpression of CDCP1 correlates with PTEN loss. To 
assess the clinical relevance of CDCP1 in human prostate can-
cer (human PCa), we examined 2 different tumor microarrays 
(TMAs), including a total of 990 cases spanning benign, prima-
ry, and metastatic PCa (30–32). Immunohistochemical (IHC) 
analysis showed that while a large portion of prostate tumors 
analyzed did not express CDCP1, a subset (48%) of CRPC and 
metastatic tumor samples expressed a high level of CDCP1 (Fig-
ure 1, A and B, Supplemental Figure 1A, and Tables 1 and 2; sup-
plemental material available online with this article; https://doi.
org/10.1172/JCI131133DS1). In line with these findings, analysis 
of consecutive tumor samples from a longitudinal study revealed 
that CDCP1 was upregulated in PCa patients during the transi-
tion from hormone-sensitive to CRPC (Supplemental Figure 1B). 
Intriguingly, high levels of CDCP1 correlated with decreased 
levels of PTEN in both primary, CRPC, and metastatic prostate 
tumor samples (Figure 1, C and D, and Tables 3 and 4). PTEN 
is one of the most frequently altered tumor suppressor genes 
in PCa, where it accounts for prostate tumor initiation and pro-
gression (5). The frequency of tumors displaying a low level of 
Table 1. CDCP1-positive samples in BPH, RPE, CRPC, and 
metastatic PCa in human prostate cancers
BPH RPE CRPC Metastasis
Total 45 382 102 35
CDCP1-positive 4 65 45 18
For TMA1, n = 564.
 
Table 2. CDCP1 membranous staining in TMA1 tumors from BPH/




The χ2 test was used for statistical analysis. χ2 = 29.9301. P < 0.00001. The 
result is significant at P < 0.05.
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form of CDCP1 (CDCP1-delta) lacking Src-phosphorylation sites 
(35, 36) in Drosophila melanogaster. The Drosophila larval imaginal 
discs are a monolayer epithelium that is considered morpholog-
ically comparable to mammalian epithelia and therefore consti-
tutes an ideal system in which to model cancer progression in vivo 
(37). Increased EGFR/Ras signaling has been previously shown to 
promote the formation of bristles located on the dorsal part of the 
fly thorax (notum) (also referred to as macrochaetae formation), 
grade PIN (HGPIN) lesions after 14 months of age with 100% pen-
etrance and showed high Ki67 expression (Figure 2, A–D, and Sup-
plemental Figure 2G). In parallel, Western blot analysis revealed 
a significant increase of Src and Erk1/2 phosphorylation in the 
prostatic epithelium of CDCP1 mice and CDCP1+ mouse embry-
onic fibroblast (MEFs) derived from this model (Figure 2, E and F). 
To further validate these findings in a different model, we over-
expressed both WT human CDCP1 (CDCP1-WT) and an inactive 
Figure 1. Advanced and metastatic prostate tumors exhibit elevated expression of CDCP1 and overexpression of CDCP1 correlate with PTEN loss. (A) 
Representative images of IHC staining of CDCP1 in benign prostate hyperplasia (BPH), CRPC, and distant metastasis of PCa in human prostate cancer 
TMA1. Scale bar: 300 μm. (B) Percentage of CDCP1-positive samples in BPH, preradical prostatectomy (RPE), CRPC, and metastatic PCa in human prostate 
cancer TMA1 (n = 564). (C) Representative images of IHC staining of CDCP1 and PTEN in 2 different PCa patients. Scale bar: 300 μm. (D) Pie graph showing 
the percentage of PTEN-high/CDCP1–, PTEN-high/CDCP1–, PTEN-high/CDCP1+, PTEN-low/CDCP1– and PTEN-low/CDCP1+ in primary tumors and CRPC/
metastasis. (E) Association of PTEN genomic loss to CDCP1 gene expression in TCGA (left panel) and Taylor data set (right panel) (5). Error bars indicate 
SEM; statistical test: Kruskal-Wallis. (F) Association of PTEN and CDCP1 expression levels with disease-free survival in the indicated patient data sets. In 
the Taylor data set, low PTEN indicates patients with expression signal lower than 8.74, and high CDCP1 indicates patients with expression signal higher 
than 11.19. In TCGA, low PTEN indicates patients with expression signal lower than 10.19, and high CDCP1 indicates patients with expression signal higher 
than 9.49. HR, hazard ratio. Statistical test: Mantel-Cox.
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the molecular level, Western blot analysis revealed that CDCP1 
Ptenpc–/– tumors showed elevated levels of Src and p-Erk1/2, where-
as p-Akt was not changed compared with Ptenpc–/– tumors (Figure 
3F). Since activated Src is known to regulate c-Myc levels (41–43), 
we reasoned that CDCP1 overexpression could drive c-Myc over-
expression through Src. Indeed, CDCP1-overexpressing tumors 
showed increased levels of c-Myc expression (Figure 3F). Further-
more, IHC analysis revealed high levels of c-Myc and pErk1/2 in 
CDCP1 Ptenpc–/– tumors compared with Ptenpc–/– tumors (Figure 3G).
We next checked whether CDCP1 could also promote resis-
tance to androgen deprivation therapy (ADT) in the same setting. 
To this end, we performed surgical castration in both Ptenpc–/– and 
CDCP1 Ptenpc–/– mice. Although Ptenpc–/– tumors responded to cas-
tration as previously reported (44), CDCP1 Ptenpc–/– did not, as 
shown by tumor weight, volume, histopathological analysis, and 
IHC for Ki-67 (Supplemental Figure 5, A–D). Resistance to castra-
tion in CDCP1 Ptenpc–/– tumors was associated with higher levels of 
p-Src, p-Erk1/2, and c-Myc when compared with Ptenpc–/– tumors, 
thus explaining the emergence of CRPC in this genetic background 
(Supplemental Figure 5, E–G). These data were additionally vali-
dated in vivo by overexpressing CDCP1 in TRAMP-C1 mouse 
prostate epithelial cells injected into C57BL/6 mice (TRAMP-C1- 
CDCP1). Overexpression of CDCP1 in TRAMP-C1 cells signifi-
cantly increased the levels of p-Src and p-Erk (Supplemental Fig-
ure 5H), accelerated the emergence of castration-resistant prostate 
cancer, and shortened the survival of TRAMP-C1-CDCP1 mice 
when compared with the control group (Supplemental Figure 5I).
Overexpression of CDCP1 bypasses the SMAD4 senescence barri-
er through activation of the Src/MAPK/Myc axis. Previous evidence 
demonstrated that Ptenpc–/– mice develop indolent tumors character-
ized by a senescence response that acts as an intrinsic barrier to con-
strain prostate cancer progression (11, 12). Since CDCP1 accelerates 
tumor progression in Ptenpc–/– mice, we tested whether CDCP1 over-
expression in this genetic background could promote senescence 
evasion both in vitro and in vivo, leading to metastasis. Prostate sec-
tions of the various genotypes (WT, CDCP1, Ptenpc–/–, and CDCP1 
Ptenpc–/–) were analyzed for senescence response by performing 
SA-β-gal and p-HP1γ staining, 2 markers of senescence in vivo 
(45). Although Ptenpc–/– tumors exhibit a strong cellular senescence 
response, CDCP1 Ptenpc–/– tumors stained negative for both SA-β-gal 
and p-HP1γ and positive for Cyclin D1, a marker of cell prolifera-
tion, thereby demonstrating that CDCP1 bypasses the senescence 
response driven by Pten loss (Figure 4A). CDCP1 Pten–/– MEFs also 
stained negative for SA-β-gal and exhibited increased cell prolifera-
tion with an elongated phenotype when compared with Pten–/– MEFs 
(Supplemental Figure 6A).
a tumor-like phenotype (35, 36). We found that overexpression of 
CDCP1-WT, but not CDCP1-delta, promoted extra macrochaetae 
formation. Note that both CDCP1 isoforms localized at the cell 
membrane of the salivary gland of the fly, as assessed by costain-
ing of E-cadherin, and presented similar expression levels (Supple-
mental Figure 3, A–C, arrows). Interestingly, loss of 1 allele (50% 
reduction) of src42A and src64B (35, 38, 39), the 2 Src homologs 
in Drosophila, suppressed extra macrochaetae formation driven by 
the overexpression of CDCP1-WT, demonstrating that this pheno-
type is Src-dependent (Supplemental Figure 3D). Collectively, this 
cross-species genetic approach demonstrates that CDCP1 overex-
pression in vivo initiates tumorigenesis.
CDCP1 cooperates with Pten loss to drive prostate cancer progres-
sion and metastasis. To further model the interplay existing between 
PTEN and CDCP1 in vivo, we crossed CDCP1 mice with Pten-null 
prostate conditional mice (Ptenpc–/–) to obtain CDCP1 Ptenpc–/– dou-
ble mutant mice. Although monoallelic loss or mutations in PTEN 
is associated with benign prostate tumors (34, 40), complete loss of 
PTEN is frequently observed in human metastatic prostate cancer 
(5). However, complete loss of Pten in the mouse is not sufficient to 
promote metastatic prostate cancer and additional genetic hits are 
needed to promote the onset of metastases (12). Strikingly, by the 
age of 25 weeks, CDCP1 Ptenpc–/– mice developed focally invasive 
adenocarcinoma, which progressed to highly aggressive carcinoma 
at later time points, a phenotype that is never observed in Ptenpc–/– 
mice (Figure 3A). Notably, the macroscopic analysis showed a sig-
nificant increase in weight and volume of CDCP1 Ptenpc–/– tumor 
compared with its counterparts (Figure 3B). Importantly, histo-
pathological analysis of CDCP1 Ptenpc–/– mice revealed metastatic 
spread of epithelial tumor nodules, positive for Pan-Cytokeratin 
(PanK), CDCP1, and AR, to draining lumbar lymph nodes in 50% 
(n = 4/8) and to the lung in 11% (n = 1/9) of the cases analyzed (Fig-
ure 3C and Supplemental Figure 4, A and B). The histological fea-
tures of these metastases resembled those of the primary prostate 
tumors (Supplemental Figure 4A). By contrast, Ptenpc–/– mice did 
not develop metastasis, as previously reported (12–14). Moreover, 
MEFs derived from CDCP1 Pten–/– mice showed an increased pro-
liferative and migratory capacity when compared with Pten–/– cells 
(Supplemental Figure 4, C and D). Additionally, Kaplan-Meier 
cumulative survival analysis showed that CDCP1 Ptenpc–/– mice died 
or had to be euthanized due to extensive tumor burden at the age 
of 60 to 80 weeks (Figure 3D). Of note, none of the age-matched 
Ptenpc–/– mice died, indicating a profound effect of CDCP1 overex-
pression on the survival of Ptenpc–/– mice. Moreover, the percentage 
of Ki-67 positive cells was significantly higher in CDCP1 Ptenpc–/– 
mice when compared with their counterpart mice (Figure 3E). At 
Table 3. PTEN and CDCP1 membranous staining in primary TMA1 




To sheer cross-linked DNA to an average fragment, the χ2 statistical test 
was used. χ2 = 7.246. P < 0.007106. The result is significant at P < 0.05.
 
Table 4. PTEN and CDCP1 membranous staining in TMA1 tumors 




The χ2 test was used for statistical analysis. χ2 = 7.6471. P < 0.005686. The 
result is significant at P < 0.05.
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Smad4-dependent transcription, promotes senescence evasion 
by releasing Cyclin D1 expression in Pten-null cells (13, 14). Thus, 
we compared the status of several components involved in these 
pathways such as p53, p21, Smad4, Cyclin D1, and COUP-TFII in 
Two recent independent reports showed that TGFB/Smad4 
pathway upregulation triggered by PTEN loss constrains pros-
tate cancer progression by blocking Cyclin D1 transcription (13, 
14). Of interest, overexpression of COUP-TFII, which inhibits 
Figure 2. Conditional overexpression of CDCP1 initiates tumorigenesis. (A) Representative images of H&E staining of anterior prostate of WT and 
CDCP1 mice. Scale bars: 500 µm. Boxes represent regions in higher magnification in WT mice, prostatic intraepithelial neoplasia (PIN), and high-grade 
PIN (HGPIN) in CDCP1 mice. Scale bars: 125 µm. (B) Histopathological characterization and quantification of the prostate in WT and CDCP1 mice. (C) IHC 
staining of H&E and AR in representative anterior prostate gland of WT and CDCP1 mice affected by HGPIN. Scale bars: 300 μm. (D) IHC staining of Ki-67 
in representative anterior prostate of WT and CDCP1 mice older than 10 months. Scale bars: 250 µm. Quantification of Ki-67 staining in anterior prostate of 
WT and CDCP1 mice at the indicated ages (n = 3–7 for each genotype). (E) Western blot analysis of major downstream targets of CDCP1 signaling in anterior 
prostates of 4-month-old WT and CDCP1 mice. Bar graph represents the fold change of normalized p-Akt, p-Erk1/2, and p-Src to their total proteins in 
CDCP1 prostates compared with WT prostates (n = 4). (F) Western blot analysis of major downstream targets of CDCP1 signaling in mouse embryonic fibro-
blasts (MEFs) from CDCP1 transgenic mice infected with retroviral vector overexpressing GFP or Cre. Bar graph represents the fold change of normalized 
p-Akt, p-Erk1/2, and p-Src to their total proteins in transgenic MEF-CDCP1 mice infected with GFP or Cre retro-virus vectors (n = 3). Error bars indicate SD. 
*P < 0.05; **P < 0.01; ***P < 0.001. Statistical test: 2-tailed t test.
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Ptenpc–/– and CDCP1 Ptenpc–/– tumor samples. Although our analysis 
showed that Smad4 and p53 expression did not change in CDCP1 
Pten-null MEFs and tumors compared with control groups, Cyclin 
D1 and COUP-TFII levels were significantly altered (Figure 4, B 
and C, and Supplemental Figure 6, B and C). These data suggest 
that CDCP1 allows Pten-null benign tumors to acquire metastatic 
potential through the evasion of the TGFB-induced senescence 
barrier by increasing the level of COUP-TFII. We next tried to 
understand the mechanism by which CDCP1 controlled COUP-
TFII levels. Interestingly, COUP-TFII, c-Myc, and Cyclin D1 
mRNA and protein levels were significantly reduced in CDCP1 
Pten–/– MEFs upon treatment with saracatinib, a selective inhibitor 
of Src (ref. 46, Figure 4D, and Supplemental Figure 6D). Of note, 
the saracatinib treatment led to a profound arrest in the prolifera-
tion and reactivation of senescence in CDCP1 Pten–/– MEFs (Figure 
4E and Supplemental Figure 6E). Since Src controls the levels of 
c-Myc, we next checked whether c-Myc could regulate COUP-TFII 
levels. We found that c-Myc inactivation in CDCP1 Pten–/– MEFs 
phenocopied the results obtained with the Src inhibitor (Figure 4, 
F and G, and Supplemental Figure 6, F and G). In line with this 
evidence, the analysis of the COUP-TFII promoter revealed the 
presence of multiple MYC-binding sites (Supplemental Figure 
6H). Chromatin immunoprecipitation (ChIP) assays confirmed 
that c-Myc specifically binds to the promoters of COUP-TFII in 
CDCP1 Pten–/– but not to those in Pten–/– MEFs. Additional ChIP 
analysis showed increased binding of c-Myc on Cyclin D1 promot-
er and reduced Smad4 binding affinity to the promoter of Cyclin 
D1 in CDCP1 Pten–/– MEFs compared with Pten–/– (Figure 4H). Alto-
gether, these data demonstrate that in CDCP1 Ptenpc–/– tumors, 
increased levels of c-Myc promote activation of COUP-TFII, 
which prevents Smad4 from binding to the promoter of Cyclin D1.
To further assess the relevance of these findings in human 
prostate cancer cells, we checked whether inhibition of CDCP1 
could drive senescence activation in prostate cancer harboring 
elevated levels of CDCP1. We therefore depleted CDCP1 in PC3, 
a PTEN TP53–deficient human prostate cancer cell line, by using 
2 independent sh-RNAs (Supplemental Figure 7A). Remarkably, 
the silencing of CDCP1 inhibited the 3D proliferation of PC3 cells 
(Supplemental Figure 7B) and promoted senescence (Supplemen-
tal Figure 7, C and D). These results were also validated in vivo by 
injecting PC3 sh-CDCP1 and control cells in SCID mice (Supple-
mental Figure 7, E and F). Of note, CDCP1-depleted PC3 tumors 
showed a significant decrease in c-MYC, COUP-TFII, and Cyclin 
D1 levels in parallel with the reduction of SRC phosphorylation 
(Supplemental Figure 7G). Together, these data demonstrate that 
CDCP1 inhibition promotes senescence by suppressing c-MYC 
levels in human prostate cancer cells. Downregulation of CDCP1 
in LNCaP-abl cells that present an increased level of CDCP1 
compared with LNCaP parental cells decreased proliferation and 
increased senescence (Supplemental Figure 7, H–J).
Androgen deprivation induces CDCP1 expression in PTEN- 
deficient cells. Since PTEN-deficient CRPC tumors display high 
CDCP1 levels, and PTEN can regulate the levels and transcription-
al activity of AR (47), we formed the hypothesis that AR could con-
trol the levels of CDCP1. Bioinformatics analysis in CRPC cases 
revealed that AR expression and AR activity inversely correlated 
with CDCP1 expression in prostate tumors (Supplemental Figure 
8, A and B). To further validate these data in vitro, we cultured the 
androgen-sensitive PTEN-null LNCaP cell line in full androgen 
deprivation (FAD) condition (absence of androgens and presence 
of enzalutamide) for more than 40 days and waited until these 
cells developed resistance (Figure 5A). CDCP1 levels increased in 
cells resistant to enzalutamide (androgen deprivation insensitive, 
ADI) when compared with enzalutamide-sensitive cells (andro-
gen deprivation sensitive, ADS). This upregulation was associated 
with the concomitant activation of p-SRC, p-ERK1/2, and c-MYC 
and to evasion of senescence driven by enzalutamide treatment 
(ref. 48, Figure 5B, and Supplemental Figure 8C). These results 
prompted us to investigate whether AR could regulate the mRNA 
expression of CDCP1. Although FAD treatment enhanced CDCP1 
levels, dihydrotestosterone (DHT) stimulation reduced its expres-
sion at both mRNA and protein levels in LNCaP ADS cells (Figure 
5C). In addition, overexpression of AR reduced the mRNA and 
protein levels of CDCP1 in the AR– prostate cancer cell line PC3 
(Figure 5D and Supplemental Figure 8D). In contrast, overexpres-
sion of a mutated form of AR that lacked the DNA binding domain 
in PC3 failed to promote the downregulation of CDCP1 (Figure 
5E). ChIP–quantitative PCR (ChIP-qPCR) analysis in LNCAP 
cells, showed that the AR could bind to the CDCP1 proximal pro-
moter, where it inhibited CDCP1 transcription (Figure 5F).
We next investigated whether loss of PTEN was needed for the 
upregulation of CDCP1 in cells kept in FAD. Indeed, CDCP1 lev-
els increased in PTEN-null LNCaP cells but not in the PTEN-WT 
LAPC4 and VCaP cell lines kept in FAD (Figure 5G). In line with 
these findings, we found that in the ADT-insensitive cell lines PC3 
and 22RV1, FAD did not upregulate CDCP1 levels (Supplemental 
Figure 8E). Interestingly, inhibition of PI3K in LNCaP cells, but 
not in 22RV1 cells, promoted a downregulation of CDCP1 in cells 
kept in FAD (Figure 5H and Supplemental Figure 8F). This was 
associated with the concomitant upregulation of AR levels in the 
same cells. These data are in agreement with previous findings 
Figure 3. CDCP1 cooperates with Pten loss to drive prostate cancer 
progression and metastasis. (A) Representative images of H&E staining 
of anterior prostate of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice at the 
age of 10 months. Scale bars: 500 μm. Bar graph representing the percent-
age of mice with PIN, HGPIN, ADS-focal, and invasive PCa. (B) Bar graph 
representing tumor weight of Ptenpc–/– and CDCP1 Ptenpc–/– mice, insets 
represent anterior prostate of Ptenpc–/– and CDCP1 Ptenpc–/–. Scale bar: 1 cm. 
(C) Representatives images of H&E, Pan-cytokeratin (PanK), CDCP1, and 
AR staining of lumbar lymph node metastases in CDCP1 Ptenpc–/– mice at 10 
months of age (n = 4/8). Scale bars: 250 μm. Graph shows the percentage 
of mice with lymph node and lung metastasis. (D) Cumulative survival of 
WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. (E) Representative images 
of Ki-67 staining in anterior prostate of WT, CDCP1, Ptenpc–/–, and CDCP1 
Ptenpc–/– mice (3 months old). Scale bars: 125 μm. Quantification of Ki-67 
staining in anterior prostate of indicated genotypes (n = 3–4 for each gen-
otype). (F) Western blot analysis and protein fold change quantification of 
specified proteins in anterior prostate glands from the indicated genotypes 
at 20 weeks of age. Graphs show protein fold change quantification of 
p-Src, p-Erk1/2, p-Akt, and c-Myc (n = 5–7). (G) Immunohistochemistry 
staining of p-AKT, p-ERK1/2, and c-Myc of anterior prostates of WT, CDCP1, 
Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 300 μm (p-AKT, p-ERK1/2); 
200 μm (c-Myc); 50 μm (inset). Error bars indicate SD for B and E and SEM 
for F. *P < 0.05; **P < 0.01; ***P < 0.001. The following statistical tests 
were used: unpaired 2-tailed t test for B and E, log-rank (Mantel-Cox) test 
for D, and 1-tailed t test for F.
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mice and upon the establishment of tumors, mice were treated 
with enzalutamide (10 mg/kg) with or without anti–CDCP1 ILs. 
Although enzalutamide showed minor effects on tumor growth, 
the combination of enzalutamide and anti–CDCP1 ILs significant-
ly affected tumor growth (Figure 6, C and D). Note that Western 
blot analysis showed a significant increase in the levels of CDCP1 
upon enzalutamide treatment in vivo, which was abolished upon 
combination treatment (Supplemental Figure 8H). Together these 
data suggest that CDCP1 targeting agents are effective when used 
in combination with ADT.
Discussion
The present study highlights the crucial role of CDCP1 in promot-
ing prostate cancer tumorigenesis and progression, and its ability 
to drive metastasis and CRPC in cooperation with PTEN deficien-
cy. Since CDCP1 is highly expressed in mCRPC patients and can 
be easily targeted, our work opens new opportunities for combina-
torial therapies. PTEN is one of the most frequently altered tumor 
suppressor genes in human prostate cancer, whereas complete 
loss of PTEN is frequently observed in metastatic prostate cancer 
(7). Previous evidence demonstrated that Ptenpc–/– develops indo-
lent tumors characterized by a senescence response that, acting 
as an intrinsic barrier, constrain prostate cancer progression (11, 
12). However, the mechanism by which PTEN-null benign tumors 
acquire metastatic potential remained poorly understood (12–14). 
CDCP1, a transmembrane protein that acts as a substrate for SRC 
family kinases, is overexpressed in a variety of tumors and has 
been associated with cancer development, invasion, and metas-
tasis (20, 21). Although CDCP1 has been considered as an onco-
gene, recent publications demonstrate that CDCP1 inactivation 
accelerates mammary and skin tumorigenesis in the PyMT and 
SmoM2 models, respectively (25). As recently demonstrated, loss 
of CDCP1 can change the spectrum of SRC substrate phosphory-
lation in cells kept in suspension. Indeed, CDCP1 negatively reg-
ulates c-SRC and PKCd in suspended cells by sequestering these 
kinases away from their canonical substrates. As a consequence, 
SRC can phosphorylate CDK5R1/p35, thereby triggering the loss 
of ITGB1/b1-integrin inside-out activation (22).
In prostate cancer, the role of CDCP1 remains poorly char-
acterized due to the lack of an in vivo model. Previous reports 
demonstrate that CDCP1 overexpression increases cellular pro-
liferation in 2 human prostate cancer cell lines with validation of 
its elevated expression in a limited number of primary prostate 
tumor samples (28, 53). In an attempt to clarify the function of 
CDCP1 in prostate cancer, we generated the first prostate-specific 
CDCP1-overexpressing transgenic mouse model and assessed the 
level of CDCP1 in different prostate cancer TMAs, including more 
than 990 cases spanning benign, primary, and metastatic prostate 
cancer. We demonstrated that CDCP1 is overexpressed in a subset 
of advanced and metastatic prostate cancers, where it is frequent-
ly associated with loss of PTEN. Moreover, we showed in vivo that 
CDCP1 cooperates with PTEN loss to promote the emergence 
of metastases and CRPC through the upregulation of the MAPK 
pathway. Previous evidence demonstrates that patients who devel-
op resistance to ADT present tumors with elevated levels of MAPK 
pathway and that activation of the MAPK pathway cooperates with 
PTEN deficiency to promote mCRPC (8, 54). Mechanistically, we 
demonstrating that PTEN loss leads to reciprocal feedback inhibi-
tion of AR activity (47). Thus, inhibition of PI3K leads to increased 
AR levels that promote the following downregulation of CDCP1.
CDCP1 targeting improves the efficacy of ADT. Given that 
androgen deprivation conditions elevate CDCP1 expression in 
ADS tumor cell lines, we postulated that compounds that block or 
degrade CDCP1 could be ideally used in combination with ADTs 
to prevent the emergence of ADI prostate tumor cells. To assess 
this hypothesis, we used the anti-CDCP1 monoclonal antibody 
CUB4, which binds the N-terminal domain of human CDCP1 and 
promotes CDCP1 internalization and degradation (27). Cotreat-
ment of LNCaP cells with CUB4 and enzalutamide strongly 
affected the proliferation of these cells by inducing senescence. In 
contrast, enzalutamide-untreated cells were only slightly affected 
by the anti-CDCP1 antibody due to the low basal levels of CDCP1 
in LNCaP cells (Supplemental Figure 8G). We next reasoned that 
tumor cell eradication rather than senescence induction could be 
a preferable outcome of CDCP1 targeting therapies (49). There-
fore, we developed an anti–CDCP1 IL carrying doxorubicin to 
eliminate CDCP1-overexpressing prostate tumor cells induced 
by the enzalutamide treatment. Note that the anti–CDCP1 IL was 
generated by using the FAB of the CUB4 antibody (27). To allow 
the selective delivery of doxorubicin to the tumor cells, the anti–
CDCP1 ILs were designed with a size of 120 nm. This size allows 
the preferential delivery of immunoliposome in tumor tissues due 
to the enhanced permeability and retention (EPR) effect of the 
cancer blood vessels (50–52).
Enzalutamide treatment, in combination with anti–CDCP1 
ILs, induced a strong apoptotic response and blocked the emer-
gence of CDCP1+ ADI cells in a time-course experiment (Figure 
6, A and B). In line with the previous experiments, treatment with 
anti–CDCP1 ILs affected the proliferation of LNCaP cells only in 
the presence of enzalutamide treatment. To validate these results 
in vivo, LNCaP cells were injected subcutaneously into SCID 
Figure 4. Overexpression of CDCP1 overcomes Pten loss–induced cellular 
senescence bypassing the SMAD4 barrier through activation of the Src/
MAPK/c-Myc axis. (A) Representative images of p-HP1γ. Senescence 
associated-β-galactosidase (SA-β-Gal) and Cyclin D1 staining in the anterior 
prostates of WT, CDCP1, Ptenpc–/–, and CDCP1 Ptenpc–/– mice. Scale bars: 125 
μm. (B) Western blot analysis of p21, Cyclin D1, COUP-TFII, Smad4, and p53 
in anterior prostate glands from the indicated genotypes. (C) qRT-PCR anal-
ysis of c-Myc, Cyclin D1, COUP-TFII, p21, p27, and p16 expression in prostates 
from 12- to 16-week-old Ptenpc–/– and CDCP1 Ptenpc–/– mice (n = 3). (D) West-
ern blot analysis of Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib 
(100 nM) for 12 hours. (E) Representative images of SA-β-Gal staining in 
Pte–/– and CDCP1 Pten–/– MEFs treated with saracatinib (100 nM) and DMSO 
for 12 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth 
by crystal violet in Pten–/– and CDCP1 Pten–/– MEFs treated with saracatinib 
(100 nM) or DMSO as control (n = 3). (F) Western blot analysis of Pten–/– 
and CDCP1 Pten–/– MEFs transfected with si-c-Myc and control si-scramble 
(si-Ctrl) after 48 hours. (G) Representative images of SA-β-Gal staining in 
Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc and si-Ctrl after 
48 hours. Scale bars: 125 μm. Bar graph shows the fold change in growth by 
crystal violet in Pten–/– and CDCP1 Pten–/– MEFs transfected with si-c-Myc 
and si-Ctrl (n = 3). (H) Schemes of Cyclin D1 and COUP-TFII promoters. qRT-
PCR of ChIP-analysis showing the binding of c-Myc to COUP-TFII promoter 
and c-Myc and Smad4 to Cyclin D1 promoters in Pten–/– and CDCP1 Pten–/– 
MEFs. Normal mouse IgG serves as negative control (n = 2). Error bars 
indicate SD. *P < 0.05; **P < 0.01. Statistical test: 2-tailed t test.
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Figure 5. Androgen deprivation in human tumor samples and cells induces CDCP1 expression. (A) Quantification of fold change in growth by crystal 
violet in LNCaP cell line grown in full media and in FAD. Dotted lines indicate ADS and ADI phases (n = 3). (B) Western blot analysis of indicated proteins 
in LNCaP-ADS and LNCaP-ADI. Quantification of fold change in CDCP1 protein levels in LNCaP-ADS and LNCaP-ADI (n = 3). (C) qRT-PCR analysis of CDCP1 
mRNA levels in LNCaP grown in full media; FAD and stimulated with dihydrotestosterone (DHT, 1 μM, 16 hours) after being grown for 2 days in FAD. 
Western blot analysis of indicated proteins in LNCaP grown under the described conditions (n = 3). (D) qRT-PCR of CDCP1 mRNA levels in PC3 expressing 
empty vector (PC3-Ctrl) and in PC3 overexpressing full-length androgen receptor (PC3-AR). Western blot analysis and protein fold change quantification of 
indicated proteins in PC3-Ctrl and PC3-AR cell lines (n = 3). (E) qRT-PCR and Western blot analysis in PC3-Ctrl, PC3-AR, and PC3 overexpressing DNA- 
binding mutant of AR (PC3-ΔAR) of CDCP1 mRNA and indicated proteins (n = 3). (F) Scheme represents the AR binding site on CDCP1 promoter. qRT-PCR 
of ChIP-analysis showing the binding of AR to CDCP1 promoter in LNCaP cell line grown in full media; FAD after DHT stimulation. Normal mouse IgG served 
as a negative control (n = 3). (G) Western blot analysis of indicated protein in LNCaP, LAPC4, and VCaP kept in normal conditions and in FAD (n = 3). (H)  
Western blot analysis of indicated proteins in LNCaP treated with PI3K inhibitor in normal conditions or in FAD. Quantification of fold change in CDCP1 
protein levels in LNCaP untreated or treated with PI3K inhibitor in normal conditions and in FAD (n = 3). Error bars indicate SD. *P < 0.05; **P < 0.01;  
***P < 0.001; ****P < 0.0001. The following statistical tests were used: 1-way ANOVA adjusted for multiple comparisons using Tukey’s test for C, E, F, and 
H, and unpaired 2-tailed t test for B and D.
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PTEN-CDCP1 dependency (47). Although we did not formally 
prove it, we believe that AR mutations, AR splicing variants, and 
the AR rewiring may also account for the upregulation of CDCP1 
observed in metastatic prostate cancer patients not treated with 
ADT due to the lack of AR binding to the CDCP1 promoter. Ther-
apeutically, we demonstrated that CDCP1 inhibition, in combi-
nation with ADT, might represent an interesting new therapeutic 
approach in prostate cancer. Indeed, we showed that inhibition of 
CDCP1 in combination with enzalutamide has the potential for 
prostate cancer treatment. Treatment of PTEN-deficient human 
prostate tumor cells with enzalutamide promoted the upregulation 
of CDCP1 levels. This treatment rendered PTEN-null cells more 
sensitive to CDCP1 targeting agents. On the other hand, enzalut-
amide-untreated cells did not respond to CDCP1-targeting agents. 
showed that CDCP1 overexpression increases c-Myc levels in a 
Src-dependent manner. This, in turn, promotes the activation of 
COUP-TFII that further inhibits Smad4-dependent transcription. 
As a result, Cyclin D1 gets upregulated and CDCP1 Ptenpc–/– tumors 
bypass senescence and progress toward a metastatic phenotype.
Of note, we found that CDCP1 mRNA and protein levels 
increase in PTEN-deficient cells treated with enzalutamide, a 
standard of therapy for CRPC patients. Finally, we provided evi-
dence that the AR can suppress the transcription of CDCP1 in 
particular in cells carrying the loss of PTEN (Figure 5E). Overex-
pression of the AR in AR– prostate cancer cell lines significantly 
decreased CDCP1 levels, supporting our observations. The recip-
rocal feedback regulation of PI3K and androgen receptor signal-
ing in PTEN-deficient prostate cancer can explain the observed 
Figure 6. CDCP1 targeting improves the efficacy of ADTs. (A) Quantification of fold change in growth by crystal violet in LNCaP cell line untreated and 
treated with enzalutamide (10 μM) in combination with or without the immune-liposome (anti–CDCP1-ILs). Enzalutamide (10 μM) treatment lasted for 26 
days. After that, cells were treated in combination with anti–CDCP1-ILs. (B) Quantification of cell death with 7-AAD staining in cells untreated and treated 
with enzalutamide in combination with or without the anti–CDCP1-ILs (n = 4). (C) Xenografts tumor growth (mm3) of LNCaP cell line untreated or treated 
with enzalutamide in the presence or absence of the anti–CDCP1-ILs. Upon tumor establishment, mice were treated with enzalutamide (10 mg/kg) for 45 
days. After the first week of enzalutamide treatments, mice were divided into 2 groups and treated with or without the anti–CDCP1-ILs. Note that the 2 
treatments were consecutive (n = 4). (D) The model represents the role of CDCP1 in CRPC. PI3K partially blocks AR. ADT blocks AR completely and upregu-
lates CDCP1 levels. Error bars indicate SD for B and SEM for C. ***P < 0.001; ****P < 0.0001. The following statistical test was used: 1-way ANOVA adjusted 
for multiple comparisons using Tukey’s test.
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er’s recommendation. Cells were transduced with PLKO or TRIPZ 
doxycycline-inducible lentiviral construct, against human CDCP1 
gene or empty vector, obtained by Thermo Fisher Scientific (clones 
V3THS_329377 and V2THS_191307). LNCaP-abl and LAPC4 cells were 
a gift from Jean-Philippe Theurillat (Institute of Oncology Research, 
Bellinzona, Switzerland). PC3-ARs were generated by infecting them 
with retroviruses expressing full-length human AR (provided by Jean-
Philippe Theurillat). PC3-ΔARs were generated using the expression of 
human AR with the deletion of amino acids 538 to 614, deletion of AR 
DNA binding domain (Addgene, catalog 89107). LNCaP-ADI cells were 
generated from parental LNCaP by growing them in RPMI 1640 con-
taining 10% charcoal-stripped FBS. Androgen stimulation experiments 
were performed using 1 nM of the 5α-DHT (MilliporeSigma, catalog 
521-18-6). The FAD experiment was performed by culturing the cells 
in RPMI with charcoal-stripped FBS and enzalutamide. Enzalutamide 
(APExBIO, catalog A3003) was dissolved in DMSO at a concentration 
of 10 μM. The following antibodies were used for Western blotting: Tag-
Myc (BD Pharmingen, catalog 551101; 1:1000); PTEN (Cell Signaling 
Technology, catalog 9552S; 1:1000); HSP90 (Cell Signaling Technolo-
gy, catalog 4877S; 1:1000); c-Myc (Santa Cruz Biotechnology, catalog 
A713(G-4), 1:500); p21 (Abcam, catalog ab107099, 1:1000); β-actin 
(MilliporeSigma, catalog A5316; 1:5000); Cyclin D1 (Cell Signaling 
Technology, catalog 2978S, 1:1000); COUP-TFII (Perseus Proteomics, 
catalog PP-H7147-00; 1:1000); SMAD4 (Santa Cruz Biotechnology, 
catalog E0615; 1:500); p-SRC-Tyr416 (Cell Signaling Technology, cat-
alog 6943S; 1:1000); SRC (Cell Signaling Technology, catalog 2123S; 
1:1000); AKT (Cell Signaling Technology, catalog 9272S; 1:1000); 
p-AKT-S473 (Cell Signaling Technology, catalog 9171S; 1:1000); p53 
(Abcam, catalog ab131442; 1:1000); CDCP1 (Cell Signaling Technol-
ogy, catalog 4115; 1:1000); Erk1/2 (Cell Signaling Technology, catalog 
4695S; 1:1000); p-Erk1/2-T202/Y204 (Cell Signaling Technology, 
catalog 4370S; 1:1000); S6 (Cell Signaling Technology, catalog 2317S; 
1:1000); p-S6-Ser235/236 (Cell Signaling Technology, catalog 4857; 
1:1000); AR (N-20) (Santa Cruz Biotechnology, catalog SC-816; 1:500). 
For IHC the following antibodies were used: Ki-67 (Thermo Fisher Sci-
entific, clone SP6, catalog RM-9106-R7; rabbit polyclonal; unmasked 
water bath 98°C, pH 6, 20 minutes; Lab Vision dilution ready to use); 
CDCP1 (Cell Signaling Technology, catalog 4115, rabbit polyclonal; 
unmasked water bath 98°C, pH 6, 20 minutes; 1:50); p-HP1γ-Ser83 
(Cell Signaling Technology, catalog 2600, unmasked water bath 98°C, 
pH 6, 20 minutes; 1:50); Cyclin D1 (Cell Signaling Technology, catalog 
Moreover, we demonstrated in vivo that enzalutamide, in combi-
nation with a new CDCP1 immunoliposome carrying doxorubicin, 
significantly inhibits tumor progression, inducing a strong apop-
totic response. These findings demonstrate that CDCP1-targeting 
therapies should be combined with ADT to maximize the efficacy 
of this standard of treatment. Therapeutically, the use of an anti–
CDCP1 IL containing doxorubicin has several advantages. First, 
liposomes loaded with doxorubicin are already in the clinic and are 
well tolerated by cancer patients. Second, the size of anti–CDCP1 
IL allows its extravasation and accumulation preferentially at the 
tumor site due to the EPR effect (50–52). Third, the conjugation of 
the liposomes with the human FAB of the CDCP1 antibody increas-
es the specificity and permanence of the IL in tumors overexpress-
ing CDCP1, increasing its anticancer efficacy. On a negative side, 
since the anti–CDCP1 ILs have been generated with an antibody 
that recognizes human CDCP1, our experiments in mice cannot 
exclude the risk of systemic toxicities of this IL, and further experi-
ments should be carried on by using a mouse antibody.
Methods
Acquisition of MEFs. Primary MEFs were prepared as described previ-
ously from individual embryos of various genotypes (12). Briefly, MEFs 
for all genotypes were obtained by crossing male WT and Ptenlox-lox with 
female CDCP1lox-stop-lox mice. Pregnant mice were sacrificed by cervical 
dislocation 13 or 14 days postcoitum. Embryos were harvested and the 
individual MEFs were cultured in DMEM containing 10% fetal bovine 
serum and 1% penicillin-streptomycin. Primary Ptenlox/lox MEFs were 
infected with retroviruses expressing either pMSCV-CRE-PURO-
IRES-GFP or pMSCV-PURO-IRES-GFP for 48 hours and selected with 
puromycin at a concentration of 3 μg/mL and as previously described. 
All mice were maintained under specific pathogen–free conditions in 
the animal facilities of the Institute for Research in Biomedicine. Exper-
iments were performed according to state guidelines and approved by 
the local ethical committee.
Cell culture and reagents. Human prostate carcinoma cell lines 
were purchased from ATCC and maintained according to the suppli-












   














Cyclin D1 forward 5′-GCGTACCCTGACACCAATC-3′
Cyclin D1 reverse 5′-CTCCTCTTCGCACTTCTGCTC-3′
c-Myc forward 5′-CTGGACCAGGGAGTGGAGT-3′
c-Myc reverse 5′-ACGTAGTAGTCGGTTCTCA-3′
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lymph node prostate cancer metastases. The second group of TMAs 
(Figure 1, A–D, and Tables 1–4) was composed of 3 different TMAs as 
previously described (30, 31). Briefly, the first TMA included 201 BHP, 
RPE, CRPC, and metastasis samples. The second TMA included 323 
PCa samples of TUP-P and RPE. The third TMA included 82 CRPC 
samples. To determine H score, the intensity of membrane CDPC1 
staining (on a scale of 0 [no staining], 1+ [weak staining], 2+ [moder-
ate staining], and 3+ [strong staining]) was multiplied by the percent-
age of positive tumor cells. In the second group of TMAs, PTEN status 
was determined by FISH or IHC analysis as previously described (30). 
The use of the clinical samples for TMA construction was approved 
by the ethics committee of the University of Basel and the University 
of Zürich. For paired diagnostic (HSPC) and CRPC biopsies (Supple-
mental Figure 1B), patients were identified from a population of men 
with mCRPC treated at the Royal Marsden NHS Foundation Trust. All 
patients provided written informed consent and were enrolled in insti-
tutional protocols approved by the Royal Marsden NHS Foundation 
Trust Hospital (London, United Kingdom) ethics review committee 
(reference no. 04/Q0801/60). Twenty-five patients with a diagnosis 
of prostate adenocarcinoma with sufficient formalin-fixed, paraffin- 
embedded (FFPE), matched diagnostic (archival) hormone-sensitive 
prostate cancer (HSPC), and CRPC tissue for CDCP1 immunohisto-
chemistry were selected. HSPC tissue demonstrated adenocarcinoma 
and was obtained from either prostate needle biopsy (21 cases), trans-
urethral resection of the prostate (TURP; 3 cases), or bone biopsy (1 
case). CRPC tissue was obtained from the same patients through biop-
sies of bone (19 cases), lymph node (5 cases), or liver (1 case). All tissue 
blocks were freshly sectioned and only considered for IHC analyses if 
adequate material was present (≥50 tumor cells).
Bioinformatic analysis. Correlation between CDCP1 and PTEN in 
prostate cancer data sets (5, 54–57) was carried out using Spearman’s 
correlation, which estimates a correlation coefficient value R and a 
significant P value.
We retrieved gene expression and DNA methylation from The 
Cancer Genome Atlas (TCGA) and performed a correlation analysis 
between the mRNA expression level and the methylation profile of 
CDCP1 (Pearson correlation). Methylation level of CDCP1 was deter-
mined as the mean of β values within a distance of about 1000 bp from 
the transcription start site (TSS). Samples were classified into quartiles 
(Q1–Q4) based on mRNA expression level of CDP1 or according to its 
methylation. Dependency between CDCP1 expression and PTEN dele-
tions/mutations was determined using χ2 test. Survival analysis was per-
formed using the Kaplan-Meier estimator and Cox regression model.
Immunoblotting. Tissue and cell lysates were prepared with RIPA 
buffer (Cell Signaling Technology, catalog 9806) with PMSF (phenyl-
methanesulfonyl fluoride; MilliporeSigma, catalog 329-98-6). Protein 
concentrations of the lysates were measured by Pierce BCA Protein 
Assay Kit (Thermo Fisher Scientific, catalog 23225). The lysates were 
then resolved by SDS-PAGE and immunoblotted with the indicated 
antibodies. For analysis of fly tissue, wandering third-instar larvae 
were rinsed in PBS, and salivary glands were dissected out, washed in 
PBS, and homogenized in SDS sample buffer.
Real-time PCR. RNA was extracted using TRIzol Plus RNA Purifi-
cation Kit (Life Technologies, catalog 12183555). Total RNA (1 μg) was 
used for cDNA synthesis using SuperScript III Platinum One-Step qRT-
PCR Kit (Life Technologies, catalog 11732-020). Quantitative real-time 
PCR (qRT-PCR) was performed as previously described (12). Primers 
2978S); AR (N-20) (Santa Cruz Biotechnology, catalog SC-816, rabbit 
polyclonal; unmasked water bath 98°C, pH 6, 20 minutes; 1:300); wide 
spectrum cytokeratin (pankeratin) (DAKO, catalog Z0622; rabbit poly-
clonal; unmasked water bath 98°C, pH 9, 20 minutes; 1:2000). For IF, 
the following antibodies were used: E-cadherin (BD Biosciences, clone 
26, catalog 610181; mouse monoclonal; unmasked water bath 98°C, pH 
9, 20 minutes; 1:700); CK5 (Abcam, catalog ab52635; rabbit polyclonal; 
unmasked water bath 98°C, pH 9, 20 minutes; 1:500); CK8 (Abcam, cat-
alog ab59400; rabbit polyclonal; unmasked water bath 98°C, pH 9, 20 
minutes; 1:150); and CDCP1 (Cell Signaling Technology, catalog 4115, 
1:100). The E-cadherin antibody (Developmental Studies Hybridoma 
Bank [DSHB], DCAD2, 1:100) was used for the drosophila experiment 
in Supplemental Figure 3. c-Myc siRNA and negative control siRNA 
were purchased from MilliporeSigma (catalog 8024873724-000050 
and 8024873724-000060). The cells were transfected with Lipofect-
amine RNAiMAX (Invitrogen, catalog 13778-030) according to the 
manufacturer’s protocol.
Generation of GAL4-UAS-CDCP1-WT and GAL4-UAS-CDCP1-delta 
Drosophila melanogaster lines and immunofluorescence. UAS-egfr.B 
(5368), src64BP1 (7379), Src42AK10108 (10969), GMR-gal4 (1104), 
and ptc-gal4 (2017) lines were obtained from the Bloomington Dro-
sophila Stock Centre. Cultures were carried out on a cornmeal/agar 
diet, (6.65% cornmeal, 7.15% dextrose, 5% yeast, 0.66% agar supple-
mented with 2.2% nipagin and 3.4 mL propionic acid) and maintained 
at 25°C and 29°C. To overexpress human CDCP1-WT and CDCP1- 
delta, UAS transgenic lines were generated from human CDCP1-WT 
and CDCP1-delta cDNA with the following primer pair: 5′-GATATC-
CACCATGGCCGGCCTGAACTGCGGG-3′ and 5′-ACTAGTTCAAT-
GGTGATGGTGATGATG-3′. PCR was performed with Q5 high-fideli-
ty polymerase (New England Biolabs, catalog M0491S). PCR products 
were cloned using the Zero Blunt TOPO PCR Cloning Kit (Life Tech-
nologies, catalog K2800-20) before cloning into the pUAST-attB vec-
tor. The constructs were sequence-verified and the transgenic lines 
established through PhiC31 integrase-mediated transgenesis (Best-
Gene, attP site VK27). Salivary glands were dissected in PBS, fixed in 
4% paraformaldehyde (PFA) in PBS, washed in PBT (PBS containing 
0.1% Triton X-100), and incubated with primary antibodies in PAXDG 
(PBS containing 1% BSA, 0.3% Triton X-100, 0.3% deoxycholate, 
and 5% goat serum) overnight at 4°C. Tissues were washed with PBT, 
incubated with secondary antibodies in PAXDG for 5 hours at 4°C, and 
mounted in Vectashield mounting media (Vector Laboratories). Alexa 
Fluor 568-8–conjugated anti-rabbit and Alexa Fluor 488–conjugat-
ed anti-rat antibodies were used as secondary antibodies (Molecular 
Probes). Images of adult eye and bristle were taken with a Leica M165 
FC microscope equipped with SXY-I30 3M Pixel Color Camera. Fluo-
rescent images of salivary glands were taken with Leica M165 FC fluo-
rescent microscope equipped with Leica DFC 3000G digital camera.
CDCP1 protein expression in human prostate cancer. The first group 
of TMAs (Supplemental Figure 1A) was composed of 2 TMAs. The first 
TMA included benign prostate tissue and prostate cancer at different 
stages (n = 237), as previously reported (32). Spots with metastases were 
not included in the analysis, to avoid false-negative results due to poor 
fixation of tissue (mostly material from autopsies). The second TMA 
(n = 192) consisted of locally advanced, inoperable, mostly metastatic 
prostate cancer including CRPC and hormone naive (untreated) pros-
tate cancer, as previously reported (32). For distant metastasis, CDCP1 
staining was performed on 6 regular histological sections of distant and 
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ed by remote loading (DXR/HSPC 0.2:1 wt/wt) at 60°C. Free DXR 
was removed using a PD-10 desalting column and the drug loading 
was determined spectrophotometrically (λ = 477 nm) in methanol. 
The CUB4 Fab′-coupled PEG-phospholipid derivative was prepared 
by reacting the Fab′ of CUB4, obtained by enzymatic digestion of Fc 
and Fab2 reduction as described below, with maleimide-PEG-DSPE. 
The synthetized CUB4 Fab′-PEG-DSPE was then introduced on the 
liposome surface by the post-insertion technique, described below, 
to provide stealth immunoliposomes (SILs). Briefly, CUB4 was enzy-
matically digested with pepsin (1:50 wt/wt enzyme/substrate, 3 hours 
at 37°C) in 0.1 M sodium acetate at pH 3.8, followed by FPLC analy-
sis on a Superose 12 10/300 GL column using PBS pH 7.4 (flow-rate 
0.5 mL/min). The F(ab′)
2
 fragment was collected and treated for 30 
minutes at room temperature with 10 mM cysteamine to yield the Fab′ 
fragment, following purification by FPLC using 50 mM phosphate 
buffer, 150 mM NaCl, and 10 mM EDTA, pH 5. By exploiting its free 
sulfhydryl groups, Fab′ was immediately coupled (overnight at room 





-DSPE 4:1 mol/mol 





-DSPE micelles were inserted on SL surface 
(post-insertion technique) by incubation of these micelles with SL for 
1 hour at 60°C at a molar ratio of 0.05:1 PEG/HSPC to achieve SIL, 
which were purified on a Sepharose CL-4B column using PBS pH 7.4 
and Fab′ quantification by BCA assay.
Statistics. All data points are presented for quantitative data, with 
an overlay of the mean with SD and SEM (specified in the figure leg-
ends). All statistical analysis were performed using Graph Pad Prism 8 
or Microsoft Excel 2016 or R-studio. A 1- or 2-tailed Student t test was 
used for statistical analysis (as specified in the figure legends). Other 
methods of statistical analysis are indicated in the figure legends.
Study approval. All mice were maintained under specific patho-
gen–free conditions in the animal facilities of the Institute for Research 
in Biomedicine, in Bellinzona, Switzerland. Experiments were per-
formed according to state guidelines and approved by the local ethics 
committee. The PtenloxP conditional knockout mice were previously 
described (12). CDCP1 conditional overexpression was generated as 
described in the text. However, to check for correct targeting of the 
transgene, DNAs from different clones were digested with SpeI and 
analyzed for correct targeting using an internal 840-bp PstI/XbaI the 
ColA1 3′probe that hybridized also with the WT allele (33). To obtain 
the prostate-specific overexpression of CDCP1 and deletion of Pten, 
female CDCP1 and/or PtenloxP/loxP mice were crossed with male Proba-
sin-Cre4 (Pb-Cre4) transgenic mice (34). To sheer cross-linked DNA to 
an average fragment for genotyping, tail-derived DNA was subjected 
to PCR analyses. For PtenloxP/loxP genotyping, primer 1 (5′-AAAAGTTC-
CCCTGATGATGATTTGT-3′) and primer 2 (5′-TGTTTTTGAC-
CAATTAAAGTAGGCTGTG-3′) were used. For detecting the allele in 
the prostate, primer 3 (5′-TTCTCTTGAGCACTGTTTCACAGGC-3′) 
and primer 1 were used. For Pb-Cre4, primer 1 (5′-TGATGGACAT-
GTTCAGGGATC-3′) and primer 2 (5′-GCCACCAGTCTGCATGA-3′) 
were used. For CDCP1 mice, primer 1 (5′-CAAGGGAGAAGAGAGT-
GCGG-3′) and primer 2 (5′-CCCAACAATGGGGATGTAAG-3′) were 
used, both for genotyping and detecting the allele in the prostate. For 
the downregulation of CDCP1, cells were infected with PLKO-sh- 
CDCP1 and doxycycline-inducible pTripz-CDCP1-shRNA. As control 
for both vectors, we used nontarget shRNA. In the xenograft experi-
used are listed in Tables 5 and 6. All qRT-PCR data presented were nor-
malized using GAPDH, HRPT, or 18S rRNA.
ChIP assay. Cells were cultured to a confluence of 90%–95% 
and were cross-linked with 1% formalin for 10 minutes followed by 
the addition of 2.5 M glycine for 5 minutes at room temperature. The 
culture medium was aspirated and the cells were washed twice with 
ice-cold PBS. Nuclear extracts were sonicated using a Misonix 3000 
model sonicator to sheer cross-linked DNA to an average fragment 
size of approximately 500 bp. Sonicated chromatin was incubated 
for 16 hours at 4°C on a rotor with γ-bind Plus sepharose beads (GE 
Healthcare, catalog 17-0886-01) conjugated with either anti–c-Myc 
([9E10]x L0815) anti-SMAD4 ([B-8]; Santa Cruz, catalog E0615) or 
mouse-IgG antibody (Millipore, catalog 92590). After incubation, 
beads were washed thoroughly and then centrifuged. The chromatin 
was eluted from the beads, and cross-links were removed by incuba-
tion at 56°C for 12 hours. DNA was then purified using the QIAquick 
PCR Purification Kit (Qiagen, catalog 28104). The binding of the tran-
scription factor, c-Myc, on Cyclin D1 promoter was determined using 
SABiosciences’ proprietary database (DECODE, DECipherment of 
DNA Elements). The primer mixes used for ChIP assay in MEFs were 
as follows: (a) to detect Smad4 binding site (SBE) on Cyclin D1 pro-
motor: SBEChIP forward 5′-CCGCTTAGTCCCCATTCTAAAG-3′ 
and SBEChIP reverse 5′-GGCATCTCCATTCTTAATCCAG-3′; (b) to 
detect c-Myc binding on Coup-tfII promotor: COUP-TFII ChIP for-
ward 5′-GTGCGGGGACAAGTCGAGCGG-3′ and COUP-TFII ChIP 
reverse 5′-GCGGTGGTGCTGGTCGATGGG-3′; (c) to detect c-Myc 
binding on Cyclin D1 promotor: EpiTect ChIP qPCR Primer Assay For 
Mouse Ccnd1, NM_007631.2 (-)04 Kb (catalog GPM1053924(-)04A). 
The primer mix used for ChIP assay in LNCaP to detect AR binding 
site on CDCP1 promoter was: forward 5′-GAATTTGTCCTCGAT-
TCAG-3′ and reverse 5′-GCCAGAGGTCTGTTGGAC-3′. ChIP qPCR 
was performed using KAPA SYBR FAST ABI qPCR Master Mix solu-
tion (KAPA Biosystem, Roche, catalog 07959389001) on Step One 
Real-Time PCR systems (Applied Biosystems).
Proliferation and senescence assays. Proliferation assay in MEFs was 
performed by plating 104 cells per well in a 24-well plate in triplicate 
while that in human prostate cancer cell lines was performed by plat-
ing 1 × 104–2 × 104 cells per well in a 24-well plate in triplicate. Cell 
proliferation was monitored at days 0, 3, 6, and 9 whereby cells were 
fixed for 15  minutes in a solution of 10% buffered formalin washed 
with PBS (pH 7.2) and subsequently stained with 0.01% Crystal violet 
solution. Excessive staining was removed by washing the plates with 
distilled water and by drying them overnight. Crystal violet–stained 
cells were dissolved in 10% acetic acid solution for 30 minutes on a 
shaker and the extracted dye was read with a spectrophotometer at 
590 nm. Cellular senescence in vitro was assessed using the Senes-
cence β-Galactosidase Staining Kit (Cell Signaling, catalog 9860) as 
per the manufacturer’s instructions and the quantification was done 
by counting the total number of cells with Hoechst 3342, trihydrochlo-
ride, trihydrate (Invitrogen; catalog 953557).
Liposomes formulation. Stealth liposomes (SLs) were prepared 
using HSPC/CHOL/mPEG
5kDa
-DSPE at a molar ratio of 18:9:1. The 
lipid film, obtained by evaporating a chloroform solution of the com-
ponents, was hydrated with a solution of 250 mM ammonium sulfate 
(pH 5.5) and then extruded at 60°C until reaching the vesicle size of 
approximately 100 nm. The external buffer was exchanged to PBS pH 
7.4 by a PD-10 desalting column. Doxorubicin (DXR) was encapsulat-
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1. JPT provided the LNCaP-ABL and Lapc4 human prostate cancer 
cell lines and made suggestions for experimental interpretation.
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detection and hematoxylin and eosin staining.
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